Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK — Four agencies are contending in an estimated $100 million creative review for a new prescription drug from Novartis, sources said.
The drug, with the working names “Zelmac” and “Zelnorm,” is for the treatment of irritable bowel syndrome. Its generic name is “tegaserod.”
Sources said the four New York-based finalists are Interpublic Group’s McCann-Erickson and Deutsch; Cline, Davis & Mann, a healthcare agency owned by Omnicom; and WPP Group’s Ogilvy & Mather. Ogilvy sister shop MindShare, New York, handles Novartis media.
Sources
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in